Summary
The available antihyperlipidaemic drugs are generally safe and effective, and major systemic adverse effects are uncommon. However, because of their complex mechanisms of action, careful monitoring is required to identify and correct potential drug interactions. Bile acid sequestrants are the most difficult of these agents to administer concomitantly, because their nonspecific binding results in decreased bioavailability of a number of other drugs, including thiazide diuretics, digitalis preparations, β-blockers, coumarin anticoagulants, thyroid hormones, fibric acid derivatives and certain oral antihyperglycaemic agents. Although the incidence is low, nicotinic acid may cause hepatic necrosis and so should not be used with drugs that adversely affect hepatic structure or function. With the HMG-CoA reductase inhibitors, relatively new agents for which clinical data are still being accumulated, the major problems appear to be rhabdomyolysis, associated with the concomitant use of cyclosporin, fibric acid derivatives or erythromycin, and mild, intermittent hepatic abnormalities that may be potentiated by other hepatotoxic drugs. Fibrates also have the potential to cause rhabdomyolysis, although generally only in combination with HMG-CoA reductase inhibitors, and are subject to binding by concomitantly administered bile acid sequestrants. The major interaction involving probucol is a possible additive effect with drugs or clinical conditions that alter the prolongation of the QTc interval, increasing the potential for polymorphic ventricular tachycardia.
Similar content being viewed by others
References
Hunninghake DB, Hibbard DM. Influence of time intervals for cholestyramine dosing on the absorption of hydrochlorothiazide. Clin Pharmacol Ther 1986; 39: 329–34
Kauffmann RE, Azarnoff DL. Effect of colestipol on gastrointestinal absorption of chlorothiazide in man. Clin Pharmacol Ther 1973; 14: 886–90
Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol 1982; 20: 151–4
Okita GT. Species difference in duration of action of cardiac glycosides. Fed Proc 1967; 26: 1125–30
Pieroni RE, Fisher JG. Use of cholestyramine resin in digitoxin toxicity. JAMA 1981; 245: 1939–40
Bazzano G, Bazzano GS. Digitalis intoxication. Treatment with a new steroid-binding resin. JAMA 1972; 220: 828–30
Hibbard DM, Peters JR, Hunninghake DB. Effects of cholestyramine and colestipol on the plasma concentrations of propranolol. Br J Clin Pharmacol 1984; 18: 337–42
Gallo DG, Bailey KR, Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965; 120: 60–5
Hunninghake DB, Pollack E. Effect of bile acid sequestering agents on the absorption of aspirin, tolbutamide, and warfarin [abstract]. Fed Proc 1977; 36: 996
Bergman F, Heedman P-A, van der Linden W. Influence of cholestyramine on absorption and excretion of thyroxine in Syrian hamster. Acta Endocrinol 1966; 53: 256–63
Northcutt RC, Stiel JN, Hollifield JW, et al. The influence of cholestyramine on thyroxine absorption. JAMA 1969; 208: 1857–61
Forland SC, Feng Y, Cutler RE. Apparent reduced absorption of gemfibrozil when given with colestipol. J Clin Pharmacol 1990; 30: 29–32
Jones RJ, Dobrilovic L. Lipoprotein lipid alterations with cholestyramine administration. J Lab Clin Med 1970; 75: 953–66
Kivistö KT, Neuvonen PJ. The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol 1990; 30: 733–6
Fattore PC, Sirtori CR. Nicotinic acid and derivatives. Curr Opin Lipidol 1991; 2: 43–7
Ding RW, Kolbe K, Merz B, et al. Pharmacokinetics of nicotinic acid-salicylic acid interaction. Clin Pharmacol Ther 1989; 46: 642–7
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–81
Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med 1974; 84: 179–86
Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92: 77–81
Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J–34J
Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339–45
Norman DJ, Illingworth DR, Munson J, et al. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [letter]. N Engl J Med 1988; 318: 46–7
Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239–41
Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5
Tobert JA. Reply [letter]. N Engl J Med 1988; 318: 48
Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13–20
Spach DH, Bauwens JE, Clark CD, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–6
Ahmad S. Lovastatin: warfarin interaction. Arch Intern Med 1990;150: 2407
Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40 Suppl. 1: S15–8
Tse FLS, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J Pharm Sci 1993; 82: 942–7
Illingworth DR. Fibric acid derivatives. In: Rifkind BM, editor. Drug treatment of hyperlipidemia. New York: Marcel Dekker, 1991: 103–38
Ahmad S. Gemfibrozil interaction with warfarin sodium (coumadin) [letter]. Chest 1990; 98: 1041–2
Buckley MM, Goa KL, Price AH, et al. Probucol: a reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs 1989; 37: 761–800
Hunninghake DB, Bell C, Olson L. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia. Atherosclerosis 1980; 37: 469–74
Durrington PN, Miller JP. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55: 187–94
Parthasarathy S, Young SG, Witztum JL, et al. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 1986; 77: 641–4
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Farmer, J.A., Gotto, A.M. Antihyperlipidaemic Agents. Drug-Safety 11, 301–309 (1994). https://doi.org/10.2165/00002018-199411050-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199411050-00002